olympia: adjuvant olaparib delays recurrence of brca-mutant breast cancer | judy garber
Published 3 years ago • 1.1K plays • Length 5:00Download video MP4
Download video MP3
Similar videos
-
5:49
perspectives on the olympia study of adjuvant olaparib in early breast cancer | nadine tung
-
2:44
olympia: adjuvant olaparib in gbrcam, her2-negative, high-risk, early breast cancer
-
2:58
olympia: adjuvant olaparib following chemo significantly improves idfs
-
3:09
breast cancer breakthrough - prof andrew tutt on the olympia trial
-
2:47
what is a parp inhibitor? | dana-farber cancer institute | science illustrated
-
11:36
top 15 métiers les mieux payés au monde !
-
12:33
inoperable: ken’s pancreas cancer
-
44:50
liquid biopsies and early detection of breast cancer
-
1:10
olympia trial lynparza stops early breast cancer from coming back
-
6:36
adjuvant cdk4/6 inhibition in early-stage hr-positive breast cancer | ruth o'regan
-
6:18
value of olaparib in brca-mutated advanced ovarian cancer
-
6:16
asco 2021 - highlights on shifting parpi to early breast cancer: the olympia study
-
28:57
2021 force | hereditary cancer | cancer risks, screening & prevention for brca1 or brca2 mutations
-
2:18
the importance of the olympia trial for breast cancer patients
-
6:53
the story of olaparib: a life-saving cancer drug
-
2:46
preliminary data on op-1250 palbociclib in advanced/metastatic er /her- breast cancer
-
2:24
astrazeneca olaparib gets cdsco panel nod for brca mutated her2 negative breast cancer
-
2:30
high stakes of diagnosis
-
22:51
ovarcoming parp resistance in brca deficient ovarian cancers
-
1:15
dr. robson on the toxicity profile of olaparib in breast cancer
-
6:28
quality of life results from olympia